Amgen stock heads into the open after a 10.1 percent drop
Published on 09/10/2026 at 07:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock closed sharply lower in the last session, ending September 9, 2026 at a substantial loss of 10.1 percent on its primary US venue in USD terms, marking it as one of the steepest individual declines in the blue-chip space. According to a market wrap from Yahoo Finance, the stock was the major loser of the Dow, markedly underperforming the broader US indices. In the same trading session, the S&P 500 index fell around 0.5 percent, highlighting how Amgen’s move significantly exceeded the general market decline.
September 9, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) saw heavy selling pressure on September 9, 2026, with the 10.1 percent decline standing out against the more moderate drops in the S&P 500 and other major benchmarks per closing data from US exchanges and summary figures reported by outlets such as WTOP. The session came amid a broader risk-off mood tied to sharply higher energy prices and pressure on pharmaceutical names, as described in US market coverage by Yahoo Finance. That backdrop saw the Dow Jones Industrial Average drop by more than 0.7 percent, while Amgen’s double digit slide underscored stock-specific pressure on top of the wider market selloff.
Conference appearance today
Today, Amgen is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference, an investor event that can bring fresh commentary on the company’s pipeline, strategy and financial outlook. As GuruFocus reported from Amgen’s announcement dated September 9, 2026, the presentation is set for 11:30 a.m. and offers management a platform to address investors shortly after the stock’s sharp decline. The combination of the recent double digit move and today’s conference appearance means new information or tone from executives could influence sentiment around Amgen as the US session unfolds.
